Redox-dependent Regulation of Nuclear Import of the Glucocorticoid Receptor*

Kensaku OkamotoDagger , Hirotoshi TanakaDagger §, Hidesato Ogawa, Yuichi MakinoDagger , Hidetaka Eguchiparallel , Shin-ichi Hayashiparallel , Noritada YoshikawaDagger , Lorenz Poellinger**, Kazuhiko Umesono, and Isao MakinoDagger

From the Dagger  Second Department of Internal Medicine, Asahikawa Medical College, Nishikagura, Asahikawa 078-8510, the  Department of Genetics and Molecular Biology, Institute for Virus Research, Kyoto University, Shogoin, Kawahara-cho, Kyoto 606-8507, the parallel  Department of Biochemistry, Saitama Cancer Center Research Institute, Ina, Saitama 362-0800, Japan, and the ** Department of Cell and Molecular Biology, Medical Nobel Institute, Karolinska Institutet, Stockholm S-171 77, Sweden

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A number of transcription factors including the glucocorticoid receptor (GR) are regulated in a redox-dependent fashion. We have previously reported that the functional activity of the GR is suppressed under oxidative conditions and restored in the presence of reducing reagents. In the present study, we have used a chimeric human GR fused to the Aequorea green fluorescent protein and demonstrated that both ligand-dependent and -independent nuclear translocation of the GR is impaired under oxidative conditions in living cells. Substitution of Cys-481 for Ser within NL1 of the human GR resulted in reduction of sensitivity to oxidative treatment, strongly indicating that Cys-481 is one of the target amino acids for redox regulation of the receptor. Taken together, we may conclude that redox-dependent regulation of nuclear translocation of the GR constitutes an important mechanism for modulation of glucocorticoid-dependent signal transduction.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glucocorticoids are indispensable not only for maintenance of metabolic homeostasis but also for treatment of a wide variety of human disorders including inflammatory diseases (1-4). Glucocorticoids exert hormone action in target tissues via binding to the glucocorticoid receptor (GR).1 The GR, as a ligand-inducible transcription factor belonging to the nuclear receptor superfamily, is docked in the cytoplasm in the absence of hormonal ligands. Upon hormone binding, the GR dissociates from hsp90 and translocates into the nucleus to regulate target gene expression (5-8). Previous biochemical studies have proven that GR function is sensitive to redox state in vitro, most possibly via reversible modification of cysteine residues in the GR. For instance, oxidative modification of the GR decreases ligand binding and nonspecific DNA binding activities of the GR in vitro (9-13). Moreover, we have recently presented evidence demonstrating that glucocorticoid hormone action in vivo is strictly controlled by cellular redox state and cysteine-affinitive metal ions (14-19). Although a number of transcription factors have been shown to be regulated in a redox-dependent fashion (reviewed in Refs. 20-22), the molecular mechanism for redox regulation of cellular GR remains largely unknown.

From a signal transduction point of view, the glucocorticoid signal that finally influences gene expression must be transmitted to the nucleus via receptor translocation. Therefore, nuclear import of the GR is one of the key control points in regulation of glucocorticoid hormone action. In general, protein transport from the cytoplasm to the nucleus involves the nuclear localization signal (NLS), i.e. short peptide sequences that are necessary and sufficient for nuclear localization of their respective proteins (23). One of the best characterized NLS motifs is that of SV40 large tumor antigen (T-ag) (23). Nuclear import of the GR is mediated by NL1, a stretch of basic amino acids at the immediate C-terminal end of the receptor DNA binding domain, and a second significantly less characterized NLS in the ligand binding domain, NL2 (24). Whereas the NLS of SV40 T-ag consists of a short domain of basic amino acids, NL1 of the GR is a bipartite domain and confers constitutive nuclear localization of the receptor (24). In contrast, NL2 acts as a dominant negative NLS in the absence of ligands (24). A number of studies have proven that the GR shuttles between the cytoplasm and the nucleus, and subcellular localization of the GR is determined by an equilibrium of both nuclear import and export. The GR translocates to the nucleus in a ligand- and energy-dependent manner, and nuclear export of the GR also requires ATP (25-34). On the other hand, subcellular localization of certain transcription factors is conditionally regulated to confer extracellular stimulus-dependent gene expression. For example, cellular treatment with tumor growth factor-beta causes nuclear translocation of the transcription factors Smad3/Smad4 (35). Moreover, oxygen also variably modulates intracellular compartmentalization of several transcription factors including nuclear factor-kappa B (36). In the case of the GR, it is well known that glucocorticoid ligands are a unique molecular switch to trigger nuclear translocation of the receptor; however, it has not yet been documented whether the cellular redox state modulates subcellular localization of the receptor.

In the present study, we have used a fusion protein of human GR and Aequorea green fluorescent protein (GFP) to study nuclear translocation of the GR in living cells (26). Using this model system, we demonstrate that not only ligand-dependent but also ligand-independent nuclear import of the GR is negatively modulated under oxidative conditions, illustrating the critical importance of the cellular redox state in modulation of GR-mediated signal transduction.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Dexamethasone was purchased from Sigma, and other chemicals were from Wako Pure Chemical (Osaka, Japan) unless otherwise specified.

Plasmids-- The expression plasmid for the chimeric protein of GFP and the human GR, pGFP-hGR, was described previously (referred to as pCMX-GFP-hGR in Ref. 26). The construction of pCMX-GFP-VP16-GR DBD, which encodes fusion protein for GFP, VP16 transactivation domain, and the DNA binding domain (DBD) of the human GR (serine 403 to leucine 532), is described elsewhere (15). pGFP-hGR/C481S, which carries a TGT to TCT point mutation to generate a cysteine for serine substitution at position 481 in the human GR, was constructed using pGFP-hGR as a template with the QuickChangeTM site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. The oligonucleotides used were 5'-GCATGCCGCTATCGAAAATCTCTTCAGGCTGGAATGAACC-3' and 5'-GGTTCATTCCAGCCTGAAGAGATTTTCGATAGCGGCATGC-3'. pCMX-GFP-VP16-GR DBD/C481S was constructed in a similar fashion using pCMX-GFP-VP16-GR DBD as a template with the identical pair of primers. The resulting plasmid constructs were confirmed by DNA sequencing. The glucocorticoid-responsive reporter plasmid pGRE-Luc has been described elsewhere, in which the firefly luciferase gene expression is driven under the control of a tandem repeat of glucocorticoid response elements (17). The beta -galactosidase expression plasmid pCH110 (Amersham Pharmacia Biotech, Uppsala, Sweden) was used as an internal control for transfection efficiency when appropriate.

Cell Culture-- The human GR-expressing CHO cells, CHOpMTGR, were originally developed and kindly provided by Dr. Stefan Nilsson (Karo Bio, Huddinge, Sweden) and cultured in Ham's F-12 medium (Life Technologies, Inc.) (37). COS7 cells and HeLa cells were obtained from the RIKEN Cell Bank (Tsukuba Science City, Japan) and maintained in Dulbecco's modified Eagle's medium (DMEM, Iwaki Glass Inc., Chiba, Japan). CHO-K1 cells were obtained from the RIKEN Cell Bank and maintained in Ham's F-12 medium. All media used in this study were phenol red-free and supplemented with 10% fetal calf serum (FCS) and antibiotics. Serum steroids were stripped with dextran-coated charcoal (DCC), and cells were cultured in a humidified atmosphere at 37 °C with 5% CO2 unless otherwise specified.

Immunocytochemical Analysis of Subcellular Localization of the GR-- Cells grown on eight-chambered sterile glass slides (Nippon Becton & Dickinson, Tokyo, Japan) were fixed for immunostaining using a freshly prepared solution of 4% paraformaldehyde (w/v) in phosphate-buffered saline (PBS) overnight at 4 °C. Immunocytochemistry was carried out as described previously (38) with a small modification. Briefly, cells were washed five times with PBS at room temperature and incubated with anti-human GR polyclonal rabbit antibody PA1-512 (Affinity Bioreagents, Neshanic Station, NJ) at 2 µg/ml in PBS containing 0.1% Triton X-100 for 9 h at 4 °C. The cells were washed five times with PBS and incubated with biotinylated anti-rabbit Ig species-specific whole antibody from donkey at a dilution of 1:200 in PBS containing 0.1% Triton X-100 for 1 h at room temperature, and then the cells were washed five times with PBS and incubated with fluorescein isothiocyanate-conjugated streptoavidin at a dilution of 1:100 in PBS containing 0.1% Triton X-100 for 1 h at room temperature. Finally, the cells were washed five times with PBS and mounted with GEL/MOUNTTM (Biomeda Co. Ltd., Foster city, CA) and then examined by a Zeiss Axiovert 135 microscope equipped with a fluorescein isothiocyanate filter set.

Transfection and Reporter Gene Assay-- Before transfection, cell culture medium was replaced with Opti-MEM medium lacking phenol red (Life Technologies). A plasmid mixture containing pGRE-Luc in the presence or absence of pGFP-human GR expression plasmids was mixed with TransIT-LT1 reagent (Panvera Corp., Madison, WI) and added to the culture. The total amount of the plasmids was kept constant by adding an irrelevant plasmid (pGEM3Z was used unless otherwise specified). After 6 h of incubation, the medium was replaced with fresh DMEM supplemented with 2% DCC-treated FCS, and the cells were further cultured in the presence or absence of various ligands for 24 h at 30 °C to increase transactivation function of expressed GFP-hGR (26). Luciferase enzyme activity was determined using a luminometer (Berthold GmbH & Co. KG, Bad Wildbad, Germany) essentially as described before (17).

Visualization of Intracellular Trafficking of GFP Fusion Proteins in Living Cells-- For analysis of nuclear translocation of the GR in living cells, we transiently expressed GFP-tagged human GR or its mutants in COS7 cells. The cells were cultured on the silane-coated coverslips in 6-cm diameter plastic dishes, and the medium was changed to Opti-MEM medium lacking phenol red before transfection. A plasmid mixture containing 6 µg of expression plasmids for various GFP-tagged proteins was mixed with 12 µl of TransIT-LT1 reagent and added to the culture. After 6 h of incubation, the medium was replaced with DMEM supplemented with 2% DCC-treated FCS, and the cells were cultured at 37 °C for 24 h, at 30 °C for at least 4 h, and then at 37 °C thereafter. GFP was expressed at detectable levels between 24 and 72 h after transfection. Routinely, cells were used for further experiments 48 h after transfection. After various treatments, cells were examined using a Zeiss Axiovert 135 microscope enclosed by an incubator and equipped with a heating stage, a fluorescein isothiocyanate filter set, and epifluorescence with illumination from a Gixenon burner (26). Quantitative assessment of the subcellular localization of expressed GFP fusion proteins was performed according to methods described elsewhere (39). In brief, subcellular localization analysis of GFP-tagged proteins was performed by blinded observers, counting approximately 200 cells in which GFP fluorescence was detected. The GFP fluorescence-positive cells were classified into four different categories: N < C for cytoplasmic dominant fluorescence; N = C, cells having equal distribution of fluorescence in the cytoplasmic and nuclear compartments; N > C for nuclear-dominant fluorescence; and N for exclusive nuclear fluorescence.

Immunoprecipitation and Western Immunoblot Assays-- Whole cell extract was prepared by lysing cells treated with dexamethasone and/or H2O2 in 25 mM N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (pH 8.2), 1 mM EDTA, 50 mM NaCl, 2.5 mM molybdate, and 10% glycerol. Immunoprecipitation experiments, with either the anti-hsp90 IgM antibody 3G3 (Affinity Bioreagents) or control mouse IgM antibody TEPC 183 (Sigma) was carried out as described previously (40). Briefly, goat anti-mouse IgM (Sigma) was coupled to CNBr- activated Sepharose 4B (Amersham Pharmacia Biotech) by incubating in the coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3) overnight at 4 °C. Thirty-five micrograms of either the monoclonal anti-hsp90 IgM antibody or control mouse IgM antibody was then incubated with 80 µl of a 1:1 suspension of the goat anti-mouse IgM antibody coupled to Sepharose in MENG buffer (25 mM Mops (pH 7.5), 1 mM EDTA, 0.02% NaN3, 10% glycerol) on ice for 90 min. This Sepharose-adsorbed material was then pelleted and washed successively once with 1 ml of MENG buffer containing 0.5 M NaCl and twice with MENG buffer containing 20 mM sodium molybdate. After brief centrifugation, the pellet was resuspended in 80 µl of MENG buffer containing 20 mM sodium molybdate, 2 mM dithiothreitol, 0.25 M NaCl, and 2.5% (w/v) bovine serum albumin. In immunoprecipitation experiments, 66 µg of cellular protein was added to the resuspension. The reaction mixtures were incubated on ice for 90 min, after which Sepharose beads were pelleted by centrifugation and washed three times with MENG buffer containing 20 mM sodium molybdate and 2 mM dithiothreitol. Immunoprecipitated proteins were eluted by boiling in SDS sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis and electrically transferred to an Immobilon-NC Pure (Millipore Corp., Bedford, MA). Subsequently, immunoblotting was performed with a monoclonal anti-GFP antibody (CLONTECH Laboratories, Palo Alto, CA) diluted at 1:500 followed by horseradish peroxidase-conjugated sheep anti-mouse Ig (Amersham Pharmacia Biotech) diluted at 1:750. In parallel, 20 µg of whole cell extracts was independently used for immunodetection of GFP-hGR and hsp90. Western immunoblot analysis for detection of hsp90 was performed in the same membrane after stripping off the immune complex for the detection of GFP-hGR, using monoclonal mouse anti-hsp90 IgG antibody 3B6 (Affinity Bioreagents) diluted at 1:500 followed by horseradish peroxidase-conjugated sheep anti-mouse Ig diluted at 1:750. Antibody-protein complexes were visualized using the enhanced chemiluminescence method according to the manufacturer's protocol (Amersham Pharmacia Biotech). After autoradiography, intensities of the appropriate bands for GFP-hGR and hsp90 were quantified using a densitometer.

Preparation and Microinjection of Recombinant GST-NLSc-GFP Protein-- Recombinant GST-NLSc-GFP, encoding the NLS of SV40 T-ag, glutathione S-transferase (GST), and GFP, was prepared as described previously (41). Glass capillary-mediated transfer of the recombinant protein was carried out using a Leitz micromanipulator as also described previously (41). In brief, COS7 cells were plated on the silane-coated coverslips in 35-mm diameter dishes in DMEM supplemented with 2% DCC-stripped FCS and treated with or without 2 mM H2O2 for 2 h. The medium was then changed to H2O2-free medium just prior to the injection. Microinjection of the recombinant protein was performed within the ensuing 5 min (approximately 30 cells were injected per dish) and the medium was immediately changed to DMEM containing 2% DCC-treated FCS with or without 2 mM of H2O2. Subcellular localization of the protein was monitored by fluorescent microscopy, and photographs were taken at intervals of 1 min for 20 min.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inhibition of Hormone-dependent Nuclear Import of the GR by Treatment with H2O2-- We recently reported that the functional activities of the GR, including ligand binding, DNA binding, and transactivation, are strictly controlled by the cellular redox state. Since, as described in the Introduction, nuclear translocation is a prerequisite for the GR to mediate hormone signaling, we wanted to examine whether subcellular localization of the GR is modulated via redox-dependent mechanisms. For this purpose, first, we assessed whether treatment with H2O2 influenced subcellular localization of the GR by indirect immunofluorescent analysis using human GR-expressing CHOpMTGR cells. As shown in Fig. 1, we found that ligand-dependent nuclear targeting of the human GR is markedly inhibited after treatment with 1 mM H2O2, whereas pretreatment with N-acetyl-L-cysteine (NAC) effectively titrates this negative effect of H2O2. Based on these results, we decided to transiently express GFP-hGR chimeric protein (26) to perform a kinetic analysis of subcellular localization of the GR in living cells with special reference to the regulatory role of cellular redox state. In these experiments, we also examined whether the nuclear translocation process was individually controlled via a redox-dependent mechanism.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Oxidative treatment suppressed ligand-dependent nuclear translocation of the GR. The human GR-expressing CHOpMTGR cells were treated with 100 nM dexamethasone (Dex), 1 mM H2O2, and 10 mM NAC for 1 h as indicated. The subcellular distribution of the GR was immunocytochemically analyzed as described under "Experimental Procedures." Experiments were repeated for three times with almost identical results, and representative photographs are shown. Bar, 10 µm.

To this end, we tested whether GFP-hGR mimics endogenous GR in terms of ligand-dependent nuclear translocation and transactivation using COS7 cells, since those cells show relatively high transfection efficiency. After transient transfection of GFP-hGR into COS7 cells, 20-30% of the cells showed cytoplasmic green fluorescence, indicating expression of GFP-hGR fusion protein in those cells. In the absence of hormone, expressed GFP-hGR chimera localized exclusively in the cytoplasm, whereas it translocated into the nucleus in a time-dependent manner after hormone treatment (Fig. 2, and data not shown). Quantitative analysis (see "Experimental Procedures") also revealed a strict ligand concentration dependence of nuclear translocation of GFP-hGR (Fig. 2). This hormone-dependent nuclear localization of GFP-hGR correlated with reporter gene expression (data not shown). We also performed similar experiments using CHO-K1 cells and HeLa cells and found that, despite significantly lower transfection efficiency, GFP-hGR again mimics native GR in these cells as well (data not shown). Therefore, although GFP was present in the N-terminal end of the human GR, we concluded that GFP-hGR mimics the native human GR, at least with reference to ligand-dependent translocation and transactivation properties (26, 28, 33).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of ligand on subcellular localization of GFP-hGR. pGFP-hGR was transiently transfected into COS7 cells, and various concentrations of dexamethasone were added to the culture medium: 0.1 nM (open squares), 1 nM (open circles), 10 nM (filled squares), 100 nM (filled circles). Photographs were taken using a fluorescent microscope at the indicated time intervals after the addition of dexamethasone. For quantitative analysis, cells were classified according to the methods described under "Experimental Procedures," and the percentages of the cells belonging to the category N are shown. Experiments were repeated 3-5 times with almost identical results, and a representative graph is shown.

We next examined the effect of oxidative treatment on nuclear translocation of GFP-hGR in COS7 cells. As shown in Fig. 3, the rate of ligand-dependent nuclear translocation of GFP-hGR was markedly delayed upon the addition of H2O2. This suppressive effect of H2O2 was dose-dependent (Fig. 3). Indeed, in the presence of 2 mM H2O2, nuclear translocation was severely compromised even after treatment with 100 nM dexamethasone (Fig. 3). Neither distribution nor intensity of GFP fluorescence was significantly influenced after treatment with H2O2 when GFP alone was expressed in COS7 cells (data not shown and Fig. 5). To test the reversibility of H2O2-dependent suppression of nuclear translocation, GFP-hGR-expressing COS7 cells were treated with 10 mM NAC after 1-h treatment with 2 mM H2O2 and 100 nM dexamethasone. As shown in Fig. 3, NAC partially but efficiently reversed the negative effects of 2 mM H2O2, resulting in the nuclear translocation of GFP-hGR in the presence of 100 nM dexamethasone. These results strongly indicate that the suppressive effects of H2O2 can be inhibited by the addition of reducing reagents and do not appear to be related to a decrease in cell viability.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Redox regulation of nuclear translocation of GFP-hGR. GFP-hGR-expressing COS7 cells were incubated for 2 h in the absence (open circles) or presence of various concentrations of H2O2: 0.5 mM (filled triangles), 1 mM (open squares), and 2 mM H2O2 (filled and shaded circles). Then 100 nM dexamethasone was added. As indicated by the arrow, NAC was added after a 1-h incubation with dexamethasone (shaded circles). At the indicated time points after the addition of dexamethasone, the subcellular localization of GFP-hGR was quantitatively assessed, and the percentages of the category N are shown. Experiments were repeated 3-5 times with almost identical results, and a representative graph is shown.

We also compared the sensitivity to H2O2 of nuclear translocation of GFP-hGR in COS7 cells, CHO-K1, and HeLa cells, all of which revealed almost complete nuclear translocation of GFP-hGR after treatment with 100 nM dexamethasone in 2 h (data not shown). When concentration-dependent curves were compared, the different cells showed the following rank order of sensitivity to oxidative treatment: HeLa, CHO-K1, and COS7 cells. IC50 values for inhibition of nuclear translocation of GFP-hGR were 0.49, 0.78, and 1.00 mM for HeLa, CHO-K1, and COS7 cells, respectively. These data indicate that, despite variation in sensitivity to oxidative treatment, oxidative inhibition of nuclear translocation of the GR may be a general phenomenon.

Oxidative Stress Inhibits Ligand-dependent Dissociation of hsp90 from the GR-- To assess the mechanism of oxidation-mediated repression of GR nuclear translocation, we investigated whether treatment with H2O2 influenced the ligand-dependent dissociation between the GR and hsp90, since we previously have reported that oxidative treatment decreases ligand binding activity of the GR (16, 17) and ligand-dependent dissociation of hsp90 has been demonstrated to correlate with initiation of nuclear translocation (29). First, to demonstrate interaction between the GR and hsp90, we employed in coimmunoprecipitation experiments a monoclonal IgM antibody capable of recognizing both free hsp90 and hsp90 complexed with other proteins (40). These experiments revealed that GFP-hGR coprecipitated with hsp90 using whole cell extracts from pGFP-hGR-transfected COS7 cells (Fig. 4A). In contrast, only background levels of GFP-hGR were coprecipitated by control IgM antibodies (Fig. 4A), indicating that GFP-hGR as well as native human GR forms a stable complex with hsp90 in solution in the absence of ligands. The IgM anti-hsp90 antibody did not react with GFP itself (data not shown). We then examined the effect of H2O2 on GFP-hGR-hsp90 interaction. After transfection of pGFP-hGR to COS7 cells, cells were cultured in the absence or presence of 1 and 2 mM H2O2 for 2 h, exposed to 100 nM dexamethasone for 30 min and harvested, and then whole cell extracts were prepared. Fig. 4B clearly demonstrates that dissociation of hsp90 from GFP-hGR requires ligand (top part, compare lanes 2 and 3). Moreover, treatment with H2O2 appeared to partially suppress this ligand-dependent dissociation of hsp90. The intensities of the bands in lanes 4 and 5 were 22 and 48% of that of lane 2 in Fig. 4B, respectively, when analyzed densitometrically (top part). On the other hand, treatment with H2O2 did not significantly affect complex formation between GFP-hGR and hsp90 in the absence of ligand (data not shown). Western immunoblot analysis of whole cell extracts using either the anti-GFP or anti-hsp90 antibodies revealed that total amounts of expressed GFP-hGR and cellular hsp90 were not significantly affected under these experimental conditions (Fig. 4B, middle and bottom). Thus, these data suggest that oxidative treatment, most possibly via interference with ligand binding, suppresses subsequent dissociation of hsp90 from the receptor. However, note that oxidative inhibition of ligand-dependent dissociation of hsp90 is partial.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of ligand-dependent dissociation of hsp90 from the GR under oxidative condition. A, 66 µg of whole cell extracts from GFP-hGR-expressing COS7 cells were coimmunoprecipitated with hsp90-specific antibodies (anti-hsp90 Ab) or control antibodies (control Ig), as described under "Experimental Procedures," and analyzed by SDS-polyacrylamide gel electrophoresis and subsequent Western immunoblotting using anti-GFP antibodies. B, after transfection of pGFP-hGR to COS7 cells, cells were cultured in the absence or presence of 1 and 2 mM H2O2 for 2 h and then exposed to 100 nM dexamethasone (Dex) for 30 min and harvested. Whole cell extracts were prepared as described under "Experimental Procedures," and 66 µg of protein samples were coimmunoprecipitated with hsp90-specific antibodies. Immunoprecipitated proteins (top) or 20 µg of whole cell extracts (middle and bottom) were run on 7.5% SDS-polyacrylamide gel electrophoresis. Western immunoblotting was performed as described under "Experimental Procedures" using anti-GFP antibodies (top and middle) or anti-hsp90 antibodies (bottom). Mr was calculated according to the protein samples run in parallel (not shown). Filled triangles depict the position of GFP-hGR (approximate Mr is 120,000), and an open triangle shows the position of hsp90 (approximate Mr is 90,000). Experiments were repeated twice with identical results, and representative results are shown.

Hormone-independent Nuclear Translocation Is Also Negatively Modulated under Oxidative Conditions-- The segregation between the effects of oxidative treatment on hsp90 release from the GR and those on nuclear translocation of GR prompted us to consider that the effects of oxidative treatment on these two phenomena are separable, although both of these events occur subsequent to ligand binding. It has already been shown that the truncation of the ligand binding domain of the GR results in constitutive nuclear localization of the mutant receptor (41). Therefore, to eliminate the involvement of the effect on ligand-receptor interaction, we constructed the expression plasmid for the fusion protein of GFP, VP16 transactivation domain, and the DNA binding domain of the GR (15). We have already shown that this plasmid contains NL1 of the GR and constitutively localizes in the nucleus (15). After transient expression of GFP-VP16-GR DBD in COS7 cells, the cells were cultured in the presence or absence of H2O2 for 12 h, and subcellular localization of this fusion protein was analyzed using a fluorescent microscope. In the absence of H2O2, GFP-VP16-GR DBD was constitutively localized in the nucleus (Fig. 5). However, in the presence of 1 mM H2O2, part of the cells showed cytoplasmic retention of GFP fluorescence (Fig. 5). Moreover, almost all cells having GFP fluorescence revealed significant cytoplasmic fluorescent signal at 2 mM H2O2, indicating that the expressed fusion protein between GFP, VP16, and GR DBD, at least in part, docks in the cytoplasm under oxidative conditions (Fig. 5). We thus may conclude that the GR nuclear translocation process is negatively modulated in a redox-dependent mechanism even after ligand-dependent dissociation of hsp90.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of oxidative treatment on ligand-independent nuclear translocation of the GR. COS7 cells were transfected with the expression plasmid for GFP-VP16-GR DBD and cultured for 12 h in the absence or presence of H2O2. Then photographs were taken as described under "Experimental Procedures." Bar, 10 µm.

Export of the GR from the Nucleus Is Not Affected under Oxidative Conditions-- Because the trafficking of the GR between the cytoplasm and the nucleus is dynamic and bidirectional (31), the equilibrium of distribution of the GR is determined by the relationship between nuclear import and export rates. Compared with nuclear protein import, it is generally believed that the export kinetics is relatively slow. Therefore, nuclear protein transport appears to be strictly unidirectional in the short term (23). Predominantly cytoplasmic localization of the GR in the absence of hormone strongly suggests that nuclear import is a rate-limiting step. Moreover, as shown in Fig. 6, export of GFP-hGR from the nucleus to the cytoplasm was not yet completed 24 h after withdrawal of dexamethasone and was not significantly affected by the addition of 0.5-2 mM H2O2. Thus, these results strongly suggest that treatment with H2O2 largely affects nuclear import of GFP-hGR.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of oxidative treatment on nuclear export of the GR. GFP-hGR-expressing COS7 cells were treated with 100 nM dexamethasone (Dex) for 1 h to allow cells to show almost complete nuclear translocation of GFP-hGR. After withdrawal of hormone by intensive washing with PBS three times, the medium was replaced with Opti-MEM medium lacking phenol red. Then the cells were incubated in the absence (open circles) or presence of various concentrations of H2O2 (0.5 mM (open triangles), 1 mM (open squares), 2 mM (filled squares)), and subcellular localization of GFP-hGR was assessed at indicated time points. Filled circles represent the percentages of the cells belonging to category N when the cells were further cultured in the presence of 100 nM dexamethasone. Quantitative analysis was performed as described under "Experimental Procedures." Experiments were repeated three times with almost identical results, and a representative graph is shown.

Effect of Oxidative Conditions on Nuclear Import of SV40 T-ag NLS-- Next, we examined whether treatment with H2O2 affected the nuclear transport of the well characterized SV40 T-ag NLS. We microinjected a recombinant chimeric protein, GST-NLSc-GFP, which consists of GST, SV40 T-ag NLS, and GFP, into the cytoplasm of COS7 cells (42). Regardless of the presence or absence of 2 mM H2O2, all cells so far examined revealed nuclear translocation of GST-NLSc-GFP within 15 min (Fig. 7), indicating that the cytoplasmic-nuclear transport machinery is not generally affected under oxidative conditions. Considering that NL1 but not the SV40 T-ag NLS contains a cysteine residue that is well conserved among nuclear receptors (Fig. 8), we supposed that NLS of the GR, especially NL1, could be a target of redox-dependent modulation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 7.   Nuclear translocation of GST-SV40 T-ag NLSc-GFP was not affected under oxidative conditions. Recombinant GST-SV40 T-ag NLSc-GFP was prepared as described under "Experimental Procedures." After a 2-h incubation of COS7 cells in the absence or presence of 2 mM H2O2, the recombinant GST-SV40 T-ag NLSc-GFP was microinjected into the cytoplasm, and then subcellular localization of GST-SV40 T-ag NLSc-GFP was examined at intervals of 1 min for 20 min (at least 20 cells were photographed per dish). Representative photographs are shown. Bar, 10 µm.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 8.   Amino acid sequence comparison of the immediate C-terminal regions of the second zinc finger motifs of nuclear receptors. The amino acid sequences of the immediate C-terminal regions of the second zinc finger motifs of nuclear receptors are shown. hGRalpha , human glucocorticoid receptor-alpha (43); hGRbeta , human glucocorticoid receptor-beta (43); hMR, human mineralocorticoid receptor (44); hPR, human progesterone receptor (45); hAR, human androgen receptor (46); hERalpha , human estrogen receptor-alpha (47); hERbeta , human estrogen receptor-beta (48); hVDR, human vitamin D receptor (49); hTR-alpha , human thyroid hormone receptor-alpha (50); hTR-beta , human thyroid hormone receptor-beta (51); hRAR-alpha , human retinoic acid receptor-alpha (52); hRAR-beta , human retinoic acid receptor-beta (53); hRAR-gamma , human retinoic acid receptor-gamma (54); hPPAR-alpha , human peroxisome proliferator-activated receptor-alpha (55); hPPAR-delta , human peroxisome proliferator-activated receptor-delta (56); hPPAR-gamma , human peroxisome proliferator-activated receptor-gamma (57); hNOR-1, human neuron-derived orphan receptor-1 (58); hTINUR, human transcriptionally inducible nuclear receptor (59); hLXR-alpha , human liver X receptor (60); hERR-alpha , human estrogen-related receptor-alpha (61); hERR-beta , human estrogen-related receptor-beta (62); hERR-gamma , human estrogen-related receptor-gamma (62); hAd4BP, human adrenal 4 binding protein (63); hROR-alpha , human retinoic acid receptor-related orphan receptor-alpha (64); hROR-gamma , human retinoic acid receptor-related orphan receptor-gamma (65); hGCNF, human germ cell nuclear factor (66); hRXR-alpha , human retinoid X receptor-alpha (67); hRXR-beta , human retinoid X receptor-beta (68); hRXR-gamma , human retinoid X receptor-gamma (69); hTAK1/hTR4 (70); hTR2 (71); hARP-1, human apolipoprotein AI regulatory protein-1 (72); hEAR-3, human v-Erb-A-related protein (73); hHNF-4, human hepatocyte nuclear factor-4 (74). Amino acids are represented in a single letter code. Conserved amino acids are shown in boldface type, and the box represents the conserved cysteine residue.

Reduction of Redox Sensitivity of the Human GR by Substitution of Cys-481 for Ser-- To test the hypothesis that this conserved cysteine residue is a target of redox regulation, we substituted Cys for Ser at position 481 in the human GR to generate GFP-hGR/C481S and GFP-VP16-GR DBD/C481S and examined nuclear import of these fusion proteins. As shown in Fig. 9A, GFP-hGR/C481S translocated into the nucleus in a ligand-dependent fashion similar to that of wild type GFP-hGR (compare with Fig. 2). In contrast, the sensitivity to H2O2 of GFP-hGR/C481S was significantly reduced when compared with that of GFP-hGR. Treatment with 1 mM H2O2 did not significantly suppress nuclear import of GFP-hGR/C481S, and 60% of cells showed complete nuclear localization of this receptor mutant even in the presence of 2 mM H2O2 (Fig. 9A, compare with Fig. 3). Moreover, even in the presence of 1 or 2 mM H2O2, constitutive nuclear localization was observed when this conserved cysteine residue was mutated to serine in GFP-VP16-GR DBD (Fig. 9B). These results strongly indicate that NL1 of the GR is a direct target of redox regulation.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 9.   Substitution of Cys-481 for Ser reduced sensitivity of the human GR to oxidative treatment. A, GFP-hGR/C481S-expressing COS7 cells were incubated for 2 h in the absence (open circles) or presence of various concentrations of H2O2: 0.5 mM (filled triangles), 1 mM (open squares), and 2 mM H2O2 (filled circles). Then 100 nM dexamethasone was added. At the indicated time points after the addition of dexamethasone, subcellular localization of GFP-hGR/C481S was quantitatively assessed, and the percentages of the category N are shown. Experiments were repeated 3-5 times with almost identical results, and a representative graph is shown. B, COS7 cells were transfected with the expression plasmid for GFP-VP16-GR DBD/C481S fusion protein and cultured for 12 h in the absence or presence of H2O2. Then photographs were taken as described under "Experimental Procedures."


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

GFP has been developed as a protein tag for in situ and real time visualization of target proteins (75). We (26) and others (28, 33) have recently studied subcellular localization of the GR in living cells using GFP-hGR chimera. Here we again confirm that GFP-hGR exclusively docks in the cytoplasm in the absence of hormonal ligand and that nuclear translocation of GFP-hGR is strictly controlled in a ligand-dependent fashion. The kinetics of GFP-hGR translocation appears to be similar to those reported for native GR; the time for the half-maximum translocation (t1/2) is 5-10 min (Fig. 2, also compare with Refs. 24 and 27). Since not only ligand-dependent release of hsp90 and nuclear transport but also transactivational function of GFP-hGR is maintained, this translocation assay system using GFP-hGR appears to be suitable for pharmacological screening of various reagents affecting the glucocorticoid signal transduction pathway. Indeed, nonsteroidal reagents have been reported to translocate the GR to the nucleus by us (38) and others (76, 77).

In the present study, we observed that subcellular localization of both wild-type and GFP-tagged human GR is dynamically controlled by redox-dependent mechanisms. Treatment of cells with H2O2 inhibits ligand-dependent nuclear translocation of the human GR, and treatment with NAC reverses this inhibitory effect of H2O2. We have also shown that oxidative treatment impairs ligand-dependent release of hsp90 from GFP-hGR. Given the putative importance of this chaperone protein for folding of the ligand binding domain (78), this effect may be closely associated with the reduction in ligand-binding activity of the GR in cultured cells under oxidative conditions (16, 17). Moreover, we showed that ligand-independent nuclear translocation of the GR is also inhibited under oxidative conditions. Thus, oxidative stress-mediated repression of GR nuclear import may not only be related to decreased ligand binding activity and subsequent impairment of release of hsp90, but may also be related to dysfunction of the nuclear translocation process itself. Under severe oxidative conditions, general dysfunction of subcellular organs may occur, and the nuclear transport machinery itself may be generally damaged. Although GR NL1 is a bipartite motif and structurally distinct from canonical NLS motif such as that of SV40 T-ag (23), both NLS categories use, at least in part, similar transportation apparatus involving importins/karyopherins and Ran GTPase (23, 28, 79). Considering that nuclear localization of GFP-tagged SV40 T-ag NLS was not affected by treatment with H2O2, oxidative stress does not appear to generally repress the cytoplasmic-nuclear transport machinery but may rather preferentially target the GR. In addition, while SV40 T-ag NLS does not contain a cysteine residue, the N-terminal part of NL1 contains a cysteine residue that is extremely well conserved among nuclear receptors (Refs. 5 and 43-74; Fig. 8). Our present data argue that this conserved Cys-481 might confer redox dependence of nuclear import of the GR. The fact that Cys-481 for Ser substitution almost completely abolished redox sensitivity of NL1 function strongly indicates that Cys-481 is one of the regulatory amino acids involved in redox-dependent intramolecular disulfide bond formation in the GR. For example, disulfide bond formation involving this cysteine residue may result in a protein conformation that hampers efficient interaction of the GR with NLS receptor proteins, e.g. importin-alpha /karyopherin-alpha even in the presence of ligands. Under reducing conditions, NL1 may interact with NLS receptor proteins in a ligand-dependent fashion, or alternatively, this may occur after liberation from hsp90, resulting in nuclear translocation of the GR. Although this cysteine residue is well conserved among nuclear receptors (Fig. 8), the functional significance has not yet been characterized for other receptor proteins. It has previously been shown that amino acid substitution of Cys-481 to Ser, contrary to amino acid substitution of Cys-481 to Arg (80), does not affect either DNA binding or transactivation functions of the GR (81). Therefore, it will be interesting to test whether this cysteine residue generally defines redox-dependent subcellular localization of nuclear receptors.

Although several reports have already documented that treatment with H2O2 of rat liver cytosol results in a decrease in ligand binding activity of the GR in vitro, we cannot compare the concentrations of H2O2 used in those studies (i.e. 20-100 mM in Refs. 12 and 82) with those used in the present in vivo study (i.e. 0.5-2 mM). We have also observed that sensitivity to H2O2 of nuclear translocation of GFP-hGR is extremely variable among distinct cell types (see also Ref. 83 for NF-kappa B activation), and steroid hormone-inducible gene expression is suppressed at lower concentrations of H2O2 in certain cells (16, 17, 84). Among the cells that we have studied, human mammary tumor cells ZR-75-1 were most sensitive to treatment with H2O2, and expression of reporter genes for either the estrogen receptor or the GR was affected under physiological concentrations of H2O2 (Ref. 84, and data not shown). Considering that reactive oxygen species including H2O2 are known to be generated as a consequence of, for example, stimulation with cytokines (85) and phagocytosis (86, 87), repression of cellular glucocorticoid action under oxidative conditions may be physiologically important in inflammatory processes. To further confirm this model, redox sensitivity of the GR should be studied in a variety of cell types with reference to their physiological processes.

Together with our previous observations, we conclude that GR-mediated signals communicate with redox signals at multiple regulatory levels including ligand binding, nuclear translocation, DNA binding, and transcriptional activation. Although involvement of the cysteine residues is suggested in both cases, nuclear translocation of the transcription factor yAP-1, in clear contrast to the GR, is rather promoted in response to oxidative stress (88). Moreover, the multicopy suppressor of SNF1 protein 2, Msn2p, which contains two zinc finger motifs, translocates into the nucleus in response to a broad variety of stresses, e.g. exposure to heat shock, oxidative stress, ethanol, sorbate, and osmostress (89). Thus, redox-dependent modification of cysteine residues is considered to be one of the key regulatory mechanisms of protein localization within the cells. From a mechanistic point of view, it should be emphasized that not only oxidative stress but hypoxic conditions influence subcellular compartmentalization of transcription factors. Notably, nuclear translocation of the hypoxia-inducible factor 1-alpha is promoted under hypoxic conditions (39). Therefore, cells may respond to alteration in oxygen tension via variable mechanisms including segregation of distinct transcription factors. In summary, the present results suggest that the dynamic cellular responses to redox state could play an important role of the glucocorticoid signal transduction mechanism. Further analysis may be necessary to clarify not only underlying molecular mechanisms but physiological significance as well.

    ACKNOWLEDGEMENTS

We thank Dr. Stefan Nilsson for the CHOpMTGR cells, Dr. Katarina Gradin for sharing experimental materials and excellent technical advice, and Dr. Pekka J. Kallio for critical reading of the manuscript and valuable comments.

    FOOTNOTES

* This work was supported in part by grants from the Ministry of Health and Welfare of Japan; the Ministry of Education, Science, Sports, and Culture of Japan; Japan Rheumatism Association; Uehara Memorial Foundation; Akiyama Foundation; Japan Research Foundation for Clinical Pharmacology; and Ito Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Second Dept. of Internal Medicine, Asahikawa Medical College, Nishikagura, Asahikawa 078-8510, Japan. Tel.: 81-166-68-2451; Fax: 81-166-68-2459; E-mail: hirotnk{at}asahikawa-med.ac.jp.

    ABBREVIATIONS

The abbreviations used are: GR, glucocorticoid receptor; hGR, human GR; hsp90, heat shock protein 90; NLS, nuclear localization signal; T-ag, large T-antigen; GFP, green fluorescent protein; CHO, Chinese hamster ovary; DMEM, Dulbecco's modified essential medium; DCC, dextran-coated charcoal; FCS, fetal calf serum; PBS, phosphate-buffered saline; GST, glutathione S-transferase; NAC, N-acetyl-L-cysteine; DBD, DNA binding domain; Mops, 4-morpholinepropanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Boumpas, D. T., Chrousos, G. P., Wilder, R. L., Cupps, T. R., and Balow, J. E. (1993) Ann. Intern. Med. 119, 1198-1208[Abstract/Free Full Text]
  2. Tyrrell, J. B. (1995) Endocrinology and Metabolism, 3rd Ed., pp. 855-882, McGraw-Hill, Inc., New York
  3. Cole, T. J., Blendy, J. A., Monaghan, A. P., Krieglstein, K., Schmid, W., Aguzzi, A., Fantuzzi, G., Hummler, E., Unsicker, K., and Schütz, G. (1995) Genes Dev. 9, 1608-1621[Abstract]
  4. Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., and Schütz, G. (1998) Cell 93, 531-541[Medline] [Order article via Infotrieve]
  5. Evans, R. M. (1988) Science 240, 889-895[Medline] [Order article via Infotrieve]
  6. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[Medline] [Order article via Infotrieve]
  7. Glass, C. K., Rose, D. W., and Rosenfeld, M. G. (1997) Curr. Opin. Cell Biol. 9, 222-232[CrossRef][Medline] [Order article via Infotrieve]
  8. Beato, M., Herrlich, P., and Schütz, G. (1995) Cell 83, 851-857[Medline] [Order article via Infotrieve]
  9. Simons, S. S., Jr., and Pratt, W. B. (1995) Methods Enzymol. 251, 406-422[Medline] [Order article via Infotrieve]
  10. Opoku, J., and Simons, S. S., Jr. (1994) J. Biol. Chem. 269, 503-510[Abstract/Free Full Text]
  11. Bodwell, J. E., Holbrook, N. J., and Munck, A. (1984) Biochemistry 23, 1392-1398[Medline] [Order article via Infotrieve]
  12. Tienrungroj, W., Meshinchi, S., Sanchez, E. R., Pratt, S. E., Grippo, J. F., Holmgren, A., and Pratt, W. B. (1987) J. Biol. Chem. 262, 6992-7000[Abstract/Free Full Text]
  13. Hutchison, K. A., Matic, G., Meshinchi, S., Bresnick, E. H., and Pratt, W. B. (1991) J. Biol. Chem. 266, 10505-10509[Abstract/Free Full Text]
  14. Tanaka, H., Makino, Y., and Okamoto, K. (1998) Vitamins Hormones 57, 153-175
  15. Makino, Y., Yoshikawa, N., Okamoto, K., Hirota, K., Yodoi, J., Makino, I., and Tanaka, H. (1999) J. Biol. Chem. 274, 3182-3188[Abstract/Free Full Text]
  16. Okamoto, K., Tanaka, H., Makino, Y., and Makino, I. (1998) Biochem. Pharmacol. 56, 79-86[CrossRef][Medline] [Order article via Infotrieve]
  17. Makino, Y., Okamoto, K., Yoshikawa, N., Aoshima, M., Hirota, K., Yodoi, J., Umesono, K., Makino, I., and Tanaka, H. (1996) J. Clin. Invest. 98, 2469-2477[Abstract/Free Full Text]
  18. Makino, Y., Tanaka, H., Dahlman-Wright, K., and Makino, I. (1996) Mol. Pharmacol. 49, 612-620[Abstract]
  19. Tanaka, H., Makino, Y., Dahlman-Wright, K., Gustafsson, J.-Å., Okamoto, K., and Makino, I. (1995) Mol. Pharmacol. 48, 938-945[Abstract]
  20. Sen, C. K. (1998) Biochem. Pharmacol. 55, 1747-1758[CrossRef][Medline] [Order article via Infotrieve]
  21. Sen, C. K., and Packer, L. (1996) FASEB J. 10, 709-720[Abstract/Free Full Text]
  22. Sun, Y., and Oberley, L. W. (1996) Free Radical Biol. Med. 21, 335-348[CrossRef][Medline] [Order article via Infotrieve]
  23. Nigg, E. A. (1997) Nature 386, 779-787[CrossRef][Medline] [Order article via Infotrieve]
  24. Picard, D., and Yamamoto, K. R. (1987) EMBO J. 6, 3333-3340[Abstract]
  25. Hsu, S., Qi, M., and DeFranco, D. B. (1992) EMBO J. 11, 3457-3468[Abstract]
  26. Ogawa, H., Inouye, S., Tsuji, F. I., Yasuda, K., and Umesono, K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11899-11903[Abstract]
  27. Sackey, F. N. A., Haché, R. J. G., Reich, T., Kwast-Welfeld, J., and Lefebvre, Y. A. (1996) Mol. Endocrinol. 10, 1191-1205[Abstract]
  28. Carey, K. L., Richards, S. A., Lounsbury, K. M., and Macara, I. G. (1996) J. Cell Biol. 133, 985-996[Abstract]
  29. Yang, J., and DeFranco, D. B. (1996) Mol. Endocrinol. 10, 3-13[Abstract]
  30. Tang, Y., Ramakrishnan, C., Thomas, J., and DeFranco, D. B. (1997) Mol. Biol. Cell 8, 795-809[Abstract]
  31. Madan, A. P., and DeFranco, D. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3588-3592[Abstract]
  32. Tang, Y., and DeFranco, D. B. (1996) Mol. Cell. Biol. 16, 1989-2001[Abstract]
  33. Htun, H., Barsony, J., Renyi, I., Gould, D. L., and Hager, G. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4845-4850[Abstract/Free Full Text]
  34. Yang, J., Liu, J., and DeFranco, D. B. (1997) J. Cell Biol. 137, 523-538[Abstract/Free Full Text]
  35. Zawel, L., Dai, J. L., Buckhaults, P., Zhou, S., Kinzler, K. W., Vogelstein, B., and Kern, S. E. (1998) Mol. Cell 1, 611-617[Medline] [Order article via Infotrieve]
  36. Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[Medline] [Order article via Infotrieve]
  37. Alksnis, M., Barkhem, T., Strömstedt, P.-E., Ahola, H., Kutoh, E., Gustafsson, J.-Å., Poellinger, L., and Nilsson, S. (1991) J. Biol. Chem. 266, 10078-10085[Abstract/Free Full Text]
  38. Tanaka, H., Makino, Y., Miura, T., Hirano, F., Okamoto, K., Komura, K., Sato, Y., and Makino, I. (1996) J. Immunol. 156, 1601-1608[Abstract]
  39. Kallio, P. J., Okamoto, K., O'Brien, S., Carrero, P., Makino, Y., Tanaka, H., and Poellinger, L. (1998) EMBO J. 17, 6573-6586[Abstract/Free Full Text]
  40. McGuire, J., Whitelaw, M. L., Pongratz, I., Gustafsson, J.-Å., and Poellinger, L. (1994) Mol. Cell. Biol. 14, 2438-2446[Abstract]
  41. Jewell, C. M., Webster, J. C., Burnstein, K. L., Sar, M., Bodwell, J. E., and Cidlowski, J. A. (1995) J. Steroid Biochem. Mol. Biol. 55, 135-146[CrossRef][Medline] [Order article via Infotrieve]
  42. Eguchi, H., Ikuta, T., Tachibana, T., Yoneda, Y., and Kawajiri, K. (1997) J. Biol. Chem. 272, 17640-17647[Abstract/Free Full Text]
  43. Hollenberg, S. M., Weinberger, C., Ong, E. S., Cerelli, G., Oro, A., Lebo, R., Thompson, E. B., Rosenfeld, M. G., and Evans, R. M. (1985) Nature 318, 635-641[Medline] [Order article via Infotrieve]
  44. Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., and Evans, R. M. (1987) Scinece 237, 268-275[Medline] [Order article via Infotrieve]
  45. Misrahi, M., Atger, M., d'Auriol, L., Loosfelt, H., Meriel, C., Fridlansky, F., Guiochon-Mantel, A., Galibert, F., and Milgrom, E. (1987) Biochem. Biophys. Res. Commun. 143, 740-748[Medline] [Order article via Infotrieve]
  46. Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J., Higgs, H. N., Larson, R. E., French, F. S., and Wilson, E. M. (1988) Mol. Endocrinol. 2, 1265-1275[Abstract]
  47. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., and Shine, J. (1986) Science 231, 1150-1154[Medline] [Order article via Infotrieve]
  48. Ogawa, S., Inoue, S., Watanabe, T., Hiroi, H., Orimo, A., Hosoi, T., Ouchi, Y., and Muramatsu, M. (1998) Biochem. Biophys. Res. Commun. 243, 122-126[CrossRef][Medline] [Order article via Infotrieve]
  49. Baker, A. R., McDonnell, D. P., Hughes, M., Crisp, T. M., Mangelsdorf, D. J., Haussler, M. R., Pike, J. W., Shine, J., and O'Malley, B. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3294-3298[Abstract]
  50. Pfahl, M., and Benbrook, D. (1987) Nucleic Acids Res. 15, 9613[Medline] [Order article via Infotrieve]
  51. Weinberger, C., Thompson, C. C., Ong, E. S., Lebo, R., Gruol, D. J., and Evans, R. M. (1986) Nature 324, 641-646[Medline] [Order article via Infotrieve]
  52. Petkovich, M., Brand, N. J., Krust, A., and Chambon, P. (1987) Nature 330, 444-450[CrossRef][Medline] [Order article via Infotrieve]
  53. Giguère, V., Ong, E. S., Segui, P., and Evans, R. M. (1987) Nature 330, 624-629[CrossRef][Medline] [Order article via Infotrieve]
  54. Lehmann, J. M., Hoffmann, B., and Pfahl, M. (1991) Nucleic Acids Res. 19, 573-578[Abstract]
  55. Sher, T., Yi, H.-F., McBride, O. W., and Gonzalez, F. J. (1993) Biochemistry 32, 5598-5604[Medline] [Order article via Infotrieve]
  56. Schmidt, A., Endo, N., Rutledge, S. J., Vogel, R., Shinar, D., and Rodan, G. A. (1992) Mol. Endocrinol. 6, 1634-1641[Abstract]
  57. Lambe, K. G., and Tugwood, J. D. (1996) Eur. J. Biochem. 239, 1-7[Abstract]
  58. Ohkura, N., Ito, M., Tsukada, T., Sasaki, K., Yamaguchi, K., and Miki, K. (1996) Biochim. Biophys. Acta 1308, 205-214[Medline] [Order article via Infotrieve]
  59. Okabe, T., Takayanagi, R., Imasaki, K., Haji, M., Nawata, H., and Watanabe, T. (1995) J. Immunol. 154, 3871-3879[Abstract/Free Full Text]
  60. Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., and Mangelsdorf, D. J. (1995) Genes Dev. 9, 1033-1045[Abstract]
  61. Giguère, V., Yang, N., Segui, P., and Evans, R. M. (1988) Nature 331, 91-94[CrossRef][Medline] [Order article via Infotrieve]
  62. Eudy, J. D., Yao, S., Weston, M. D., Ma-Edmonds, M., Talmadge, C. B., Cheng, J. J., Kimberling, W. J., and Sumegi, J. (1998) Genomics 50, 382-384[CrossRef][Medline] [Order article via Infotrieve]
  63. Oba, K., Yanase, T., Nomura, M., Morohashi, K., Takayanagi, R., and Nawata, H. (1996) Biochem. Biophys. Res. Commun. 226, 261-267[CrossRef][Medline] [Order article via Infotrieve]
  64. Giguère, V., Tini, M., Flock, G., Ong, E., Evans, R. M., and Otulakowski, G. (1994) Genes Dev. 8, 538-553[Abstract]
  65. Hirose, T., Smith, R. J., and Jetten, A. M. (1994) Biochem. Biophys. Res. Commun. 205, 1976-1983[CrossRef][Medline] [Order article via Infotrieve]
  66. Kapelle, M., Krätzschmar, J., Husemann, M., and Schleuning, W.-D. (1997) Biochim. Biophys. Acta 1352, 13-17[Medline] [Order article via Infotrieve]
  67. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A., and Evans, R. M. (1990) Nature 345, 224-229[CrossRef][Medline] [Order article via Infotrieve]
  68. Leid, M., Kastner, P., Lyons, R., Nakshatri, H., Saunders, M., Zacharewski, T., Chen, J.-Y., Staub, A., Garnier, J.-M., Mader, S., and Chambon, P. (1992) Cell 68, 377-395[Medline] [Order article via Infotrieve]
  69. Mangelsdorf, D. J., Borgmeyer, U., Heyman, R. A., Zhou, J. Y., Ong, E. S., Oro, A. E., Kakizuka, A., and Evans, R. M. (1992) Genes Dev. 6, 329-344[Abstract]
  70. Hirose, T., Fujimoto, W., Tamaai, T., Kim, K. H., Matsuura, H., and Jetten, A. M. (1994) Mol. Endocrinol. 8, 1667-1680[Abstract]
  71. Chang, C., and Kokontis, J. (1988) Biochem. Biophys. Res. Commun. 155, 971-977[Medline] [Order article via Infotrieve]
  72. Ladias, J. A. A., and Karathanasis, S. K. (1991) Science 251, 561-565[Medline] [Order article via Infotrieve]
  73. Wang, L.-H., Tsai, S. Y., Cook, R. G., Beattie, W. G., Tsai, M.-J., and O'Malley, B. W. (1989) Nature 340, 163-166[CrossRef][Medline] [Order article via Infotrieve]
  74. Chartier, F. L., Bossu, J. P., Laudet, V., Fruchart, J. C., and Laine, B. (1994) Gene (Amst.) 147, 269-272[CrossRef][Medline] [Order article via Infotrieve]
  75. Chalfie, M. (1995) Photochem. Photobiol. 62, 651-656[Medline] [Order article via Infotrieve]
  76. Pariante, C. M., Pearce, B. D., Pisell, T. L., Owens, M. J., and Miller, A. H. (1997) Mol. Pharmacol. 52, 571-581[Abstract/Free Full Text]
  77. Calleja, C., Pascussi, J. M., Mani, J. C., Maurel, P., and Vilarem, M. J. (1998) Nat. Med. 4, 92-96[Medline] [Order article via Infotrieve]
  78. Pratt, W. B. (1993) J. Biol. Chem. 268, 21455-21458[Free Full Text]
  79. Jans, D. A., and Hübner, S. (1996) Physiol. Rev. 76, 651-685[Abstract/Free Full Text]
  80. Zilliacus, J., Dahlman-Wright, K., Carlstedt-Duke, J., and Gustafsson, J-Å (1992) J. Steroid Biochem. Mol. Biol. 42, 131-139[Medline] [Order article via Infotrieve]
  81. Schena, M., Freedman, L. P., and Yamamoto, K. R. (1989) Genes Dev. 3, 1590-1601[Abstract]
  82. Bresnick, E. H., Sanchez, E. R., Harrison, R. W., and Pratt, W. B. (1988) Biochemistry 27, 2866-2872[Medline] [Order article via Infotrieve]
  83. Schreck, R., and Baeuerle, P. A. (1994) Methods Enzymol. 234, 151-163[Medline] [Order article via Infotrieve]
  84. Hayashi, S-I., Hajiro-Nakanishi, K., Makino, Y., Eguchi, H., Yodoi, J., and Tanaka, H. (1997) Nucleic Acids Res. 25, 4035-4040[Abstract/Free Full Text]
  85. Klebanoff, S. J., Vadas, M. A., Harlan, J. M., Sparks, L. H., Gamble, J. R., Agosti, J. M., and Waltersdorph, A. M. (1986) J. Immunol. 136, 4220-4225[Abstract/Free Full Text]
  86. Tsan, M.-F., Douglass, K. H., and Mclntyre, P. A. (1977) Blood 49, 437-444[Abstract]
  87. Shepherd, V. L. (1986) Semin. Respir. Infect. 1, 99-106[Medline] [Order article via Infotrieve]
  88. Kuge, S., Jones, N., and Nomoto, A. (1997) EMBO J. 16, 1710-1720[Abstract/Free Full Text]
  89. Görner, W., Durchschlag, E., Martinez-Pastor, M. T., Estruch, F., Ammere, G., Hamilton, B., Ruis, H., and Schüller, C. (1998) Genes Dev. 12, 586-597[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.